clinical trial · NCT06005441
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
Caliway Biopharmaceuticals Co., Ltd.·phase2·completed·n = 173
Subcutaneous FatCBL-514 injectionCBL-A1 InjectionCBL-A2 Injection0.9% Sodium Chloride
brief summary
This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.
started
Nov 10, 2023
primary completion
Oct 18, 2024
completion
Oct 18, 2024
last updated
Dec 5, 2024
detailed description
A total of approximately 160 adult participants with moderate or severe abdominal fat at Screening will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 3 weeks.
official title
A Phase 2b, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection Compared With CBL-A1 and CBL-A2 for Reducing Abdominal Subcutaneous Fat
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol